Rein Therapeutics Inc (RNTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,808 | 5,219 | 4,864 | 7,653 | 7,474 |
| Marketable Securities | 8,938 | 16,048 | 20,638 | 24,754 | 30,626 |
| TOTAL | $17,105 | $21,873 | $27,054 | $33,550 | $39,993 |
| Non-Current Assets | |||||
| PPE Net | 52 | 70 | 84 | 98 | 113 |
| Other Non-Current Assets | 0 | 64 | 94 | 122 | 149 |
| TOTAL | $52 | $134 | $178 | $220 | $262 |
| Total Assets | $17,157 | $22,007 | $27,232 | $33,770 | $40,255 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 458 | 1,720 | 945 | 1,741 | 1,023 |
| Accrued Expenses | 2,426 | 1,631 | 3,524 | 3,310 | 2,992 |
| TOTAL | $2,884 | $3,384 | $4,536 | $5,151 | $4,146 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $2,884 | $3,384 | $4,536 | $5,151 | $4,146 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 4,541 | 4,541 | 4,541 | 4,541 | 4,541 |
| Common Shares | 91 | 91 | 91 | 91 | 91 |
| Retained earnings | -277,564 | -272,785 | -268,238 | -261,870 | -253,878 |
| Other shareholders' equity | -10 | -48 | -98 | -101 | -75 |
| TOTAL | $14,273 | $18,623 | $22,696 | $28,619 | $36,109 |
| Total Liabilities And Equity | $17,157 | $22,007 | $27,232 | $33,770 | $40,255 |